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Background. Vulvovaginal candidiasis is characterized by curd-like vaginal discharge and itching, and is associated with
considerable health and economic costs. Materials and Methods. We examined the incidence, prevalence, and risk factors for
vulvovaginal candidiasis among a cohort of 898 women in south India. Participants completed three study visits over six months,
comprised of a structured interview and a pelvic examination. Results. The positive predictive values for diagnosis of vulvovaginal
candidiasis using individual signs or symptoms were low (<19%). We did not find strong evidence for associations between
sociodemographic characteristics and the prevalence of vulvovaginal candidiasis. Women clinically diagnosed with bacterial
vaginosis had a higher prevalence of vulvovaginal candidiasis (Prevalence 12%, 95% CI 8.2, 15.8) compared to women assessed
to be negative for bacterial vaginosis (Prevalence 6.5%, 95% 5.3, 7.6); however, diﬀerences in the prevalence of vulvovaginal
candidiasis were not observed by the presence or absence of laboratory-confirmed bacterial vaginosis. Conclusions. For correct
diagnosis of vulvovaginal candidiasis, laboratory confirmation of infection with Candida is necessary as well as assessment of
whether the discharge has been caused by bacterial vaginosis. Studies are needed of women infected with Candida yeast species to
determine the risk factors for yeast’s overgrowth.
1. Introduction
Vulvovaginal candidiasis is caused by overgrowth of Candida
yeast species in the vagina and is characterized by curd-like
vaginal discharge, itching, and erythema [1]. Vulvovaginal
candidiasis has been associated with considerable direct and
indirect economic costs [2], enhanced susceptibility to HIV
infection [3], and is being investigated for a potential rela-
tionship with preterm birth [4]. Treatment of vulvovaginal
candidiasis is warranted when a woman presenting with a
complaint of symptoms consistent with vulvovaginal can-
didiasis also has laboratory confirmation of the presence of
Candida from a vaginal specimen. Short-course azole-based
treatment regimens are considered eﬀective and safe [5] and
are accessible and aﬀordable in most settings.
Much of the epidemiologic literature concerning vul-
vovaginal candidiasis reports on studies in which women
were queried on their self-reported history of vulvovaginal
candidiasis [6], but without laboratory-confirmation of
infection by Candida. Other studies, in which investigators
only measure the presence of Candida infection of the
vagina [1], are not able to identify women with symp-
tomatic vulvovaginal candidiasis disease; this latter study
design is frequently employed for studies conducted in low-
income settings. Few studies have diagnosed vulvovaginal
candidiasis through laboratory confirmation of infection in
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symptomatic women, and few studies have measured the
incidence of confirmed cases of vulvovaginal candidiasis.
The lack of representative data on the epidemiologic
features of laboratory-confirmed vulvovaginal candidiasis
has been evident throughout the time in which vulvovaginal
candidiasis has evolved from being considered a “nuisance
infection” to a clinically relevant condition [7, 8]. In India,
only two studies have been conducted in which laboratory-
confirmed vulvovaginal candidiasis was diagnosed in a
community-based sample. Bang et al. diagnosed vulvovagi-
nal candidiasis in 35% of 650 adult women living in rural
Maharashtra state, and Prasad et al. diagnosed vulvovaginal
candidiasis in 10% of 451 married, 16–22 year old women
in rural Tamil Nadu state [9, 10]. However, neither study
assessed the incidence of or identified risk factors for
vulvovaginal candidiasis.
As reduction of HIV transmission and of adverse birth
outcomes remain public policy priorities in India [11], and
studies have shown gynecological morbidity is extremely
common [12–15], additional investigation of the epidemio-
logic features of vulvovaginal candidiasis is warranted.
2. Materials and Methods
We examined the incidence, prevalence, and potential risk
factors for vulvovaginal candidiasis among a cohort of
women originally recruited for a study to examine the
relationship of lower genital tract infections and incident
Herpes simplex virus type 2 infection [16]. The recruitment
and baseline descriptive features of the cohort of 898 sexually
active, nonpregnant women between 16 and 30 years of age
from communities aroundMysore, India has been previously
described [17, 18]. Briefly, between 2005 and 2006, women
in the cohort completed three study visits (at baseline and at
three and six months), comprised of a structured interview,
a clinical examination, and collection of cervicovaginal spec-
imens for laboratory testing. Trained interviewers collected
sociodemographic and behavioral information, as well as
reports of symptoms associated with gynecologic morbidity.
2.1. Clinical and Laboratory Methods. Study physicians per-
formed a pelvic examination of each participant and
recorded signs of vaginal abnormalities. During the exam-
ination, swabs of the posterior fornix of the vagina and
blood specimens were collected, and vaginal pH measured.
Consistent with the US Centers for Disease Control and
Prevention (CDC) 2006 diagnostic criteria [19] established
prior to the baseline visit [20], vaginal Candida infection
was assessed from culture (InTray Colorex Yeast, BioMed
Diagnostics, White City, OR, USA) though speciation of
positive samples was not recorded. Participants with positive
culture for Candida were diagnosed as having vulvovaginal
candidiasis if they reported vaginal itching or discharge
and had vaginal erythema or discharge observed on clinical
examination. As part of the Nugent-criteria scoring for
laboratory diagnosis of bacterial vaginosis [21], the average
number of Lactobacillus-like cells (morphotypes) detected
over several visual fields in light microscopy was enumerated,
and given a score corresponding to averages of 0, <1, 1–4,
5–29, and ≥30. Laboratory investigations were completed
at Holdsworth Memorial Hospital and Vikram Hospital in
Mysore, India. Clinical and laboratory diagnostic criteria for
the gynecological conditions examined in this cohort are
detailed in Table 1. Women were treated according to CDC
guidelines [19].
2.2. Statistical Methods. Our outcome measure was lab-
oratory-confirmed diagnosis of vulvovaginal candidiasis.
First, we describe prevalence and incidence of vulvovaginal
candidiasis using frequencies and percentages. We calculated
the visit-specific prevalence of vulvovaginal candidiasis and
assessed whether this prevalence changed over the course
of the study. Next, we tabulated the number of women’s
clinic visits with various vaginal symptoms reported or
vaginal signs observed. Among observations in which these
vaginal signs or symptoms were recorded, we calculated
the proportion in which a diagnosis of vulvovaginal can-
didiasis was made. Finally, we examined the relationship
between the prevalence of vulvovaginal candidiasis and
sociodemographic characteristics and possible risk factors.
Categorical variables are the same as used in previous
analyses; cut-points of previously continuous measures were
defined to create balanced strata of participants at the
baseline visit [16, 17]. We used a separate univariable
regression model for each characteristic and risk factor.
While counts (e.g., the number of diagnoses of vulvovaginal
candidiasis) are reported as observed, percentages, prev-
alences, trends in prevalence, 95% confidence intervals, and
P values were estimated using generalized estimating equa-
tions (GEE) regression models. GEE allows for parameter
estimation when observations are correlated, in this case, due
to multiple observations per participant over the course of
the study. The GEEmodels were specified with binary family,
identity link, and exchangeable correlation. The GEE models
were bootstrapped with 500 repetitions to estimate robust
standard errors.
Statistical analysis was conducted using Stata 11.2 (Stata
Corp, College Station, TX, USA). The study was approved
by the Committee for the Protection of Human Subjects at
the University of California, Berkeley, and the Asha Kiran
Institutional Review Board of Mysore, India; all participating
women provided written informed consent.
3. Results
The 898 women participating in the study contributed a total
of 2551 study visits, with 800 women (89%) attending all
three study visits and another 53 women (6%) attending two
visits. The median age of the women at the baseline visit
was 26 years (Interquartile range [IQR] 24–29 years), and
participants had been with their current sex partner for a
median of nine years (IQR 6–12 years). Over one-quarter
of the women had no formal education (27%). Nearly one
in three women identified as Muslim (29%). Few women
were nulliparous (15%), and very few women reported using
oral contraception, condoms, or an intrauterine device at any
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Table 1: Diagnostic criteria and treatment given for laboratory- and clinically-diagnosed gynecological conditions,Mysore, India 2005-2006.
Diagnosis Diagnostic criteria Laboratory device Treatment
Candida infection Positive culture
InTray Colorex Yeast,
BioMed Diagnostics,
White City, OR, USA
None
Vulvovaginal candidiasis
Positive culture for Candida infection
and one clinical sign (vaginal
erythema or discharge) and one
reported symptom (vaginal pruritis or
discharge)
150mg oral
fluconazole, single
dose
Trichomonas vaginalis
Positive culture or positive saline wet
mount microscopy
InPouch, BioMed
Diagnostics, White
City, OR, USA
2 g oral
metronidazole,
single dose
Bacterial vaginosis,
laboratory
Score of 7–10 on Nugent criteria from
Gram stain
None
Intermediate flora,
laboratory
Score of 4–6 on Nugent criteria from
Gram stain
None
Abnormal flora,
laboratory
Score of 4–10 on Nugent criteria from
Gram stain [21]
None
Bacterial vaginosis,
clinical
Positive on at least three of four Amsel
criteria (elevated pH, positive whiﬀ
test, clue cells observed, discharge
observed) [22]
400mg oral
metronidazole, bid
for 7 days
Herpes simplex virus
type 2
Index value >1.1 on ELISA test of
serum
Focus Technologies,
Cypress, CA, USA
Acyclovir 400mg
tid for 7–10 days
point during the study. Furthermore, less than 5% reported
having oral sex or having had more than one lifetime sex
partner. No woman reported douching or smoking tobacco.
Throughout the duration of the study, the mean prevalences
of reproductive tract infections were as follows: Trichomonas
vaginalis (6%), clinical diagnosis (Amsel criteria) of bacterial
vaginosis (12%), laboratory diagnosis (Nugent criteria) of
bacterial vaginosis (16%), and infection with Herpes simplex
virus-type 2 (13%). At least 30 Lactobacillus morphotypes
were detected on the majority (66%) of Gram stains of
vaginal swabs, with smaller proportions of swabs with 5–29,
1–4, <1, and 0 morphotypes detected (11, 5, 6, and 12%,
resp.).
3.1. Vaginal Signs and Symptoms and Diagnosis of Vulvovagi-
nal Candidiasis. Including all three study visits for which
laboratory confirmation for diagnosis of vulvovaginal can-
didiasis was available (n = 2528/2551, 99%), we found that
substantial proportions of the women reported vaginal
itching (29%) or vaginal discharge (31%) or had vaginal
erythema (9%) or vaginal discharge (35%) on examination.
The positive predictive values of these signs and symptoms
for predicting vulvovaginal candidiasis were low. A minority
of women with these symptoms or signs was subsequently
diagnosed with vulvovaginal candidiasis (18, 15, 25, and
18%, resp.). Combinations of the vaginal signs and symp-
toms were increasingly rare, though the probability of a
correct diagnosis of vulvovaginal candidiasis increased to
41% when both signs and both symptoms were present
(Table 2).
3.2. Diagnosis, Prevalence, and Incidence of Vulvovaginal Can-
didiasis. Candida was detected in 885/2528 (35%) vaginal
specimens tested on culture. Of the 885, 180 (20%) satisfied
the case definition for diagnosis of vulvovaginal candidiasis,
while the remaining 705 (80%) were considered asymp-
tomatic infection.
The prevalence of vulvovaginal candidiasis declined over
the three study visits from 77/893 (9%) at baseline to 65/840
at three months (8%) and 38/795 (5%) at six months (P
value for trend < 0.001). The incidence of vulvovaginal
candidiasis was modest: Of the 1487 baseline or three
month study visits in which a woman was not diagnosed
with vulvovaginal candidiasis, 72 (5%) were positive for
vulvovaginal candidiasis at the next study visit. Repeat
diagnoses of vulvovaginal candidiasis were common. Of the
137 baseline or three-month study visits in which a woman
was diagnosed with vulvovaginal candidiasis, 30 (28%) were
again diagnosed with vulvovaginal candidiasis at the next
study visit.
3.3. Cross-Sectional Analysis of Vulvovaginal Candidiasis. We
did not find strong evidence for associations between socio-
demographic characteristics and the diagnosis of vulvovagi-
nal candidiasis. The prevalence of vulvovaginal candidiasis
among women who first had sex before 15 years of age
(Prevalence 4.4%, 95% CI 2.6, 6.3) appeared lower than
for women who first had sex between 15 and 18 years
(Prevalence 7.5%, 95% CI 6.1, 9.0) or over 19 years of
age (Prevalence 8.2%, 95% CI 5.5, 11.0). There was a
large diﬀerence in the prevalence of vulvovaginal candidiasis
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Table 2: Prevalence of observed clinical signs, reported symptoms, and diagnosis (positive predictive value) of vulvovaginal candidiasis,
Mysore, India 2005-2006.
Vaginal sign observed
or symptom reported
Prevalence
(n = 2528
clinical visits)
% prevalence
(95% CI)∗∗
Diagnosed with
vulvovaginal
candidiasis
% diagnosed with
vulvovaginal candidiasis
(95% CI)∗∗
Pruritis reported 735 29.0 (26.8, 31.2) 132 17.8 (14.8, 20.8)
Discharge reported 782 31.0 (29.0, 32.9) 122 15.3 (12.5, 18.1)
Erythema observed 239 9.5 (8.2, 10.8) 61 24.8 (18.7, 30.8)
Discharge observed 894 35.4 (33.4, 37.5) 162 17.6 (14.9, 20.3)
None 887 35.1 (33.0, 37.2) — —
Any one 916 36.2 (34.3, 38.1) — —
Any two 492 19.5 (17.8, 21.1) 84 16.7 (13.3, 20.1)
Any three 182 7.2 (6.1, 8.3) 75 40.1 (33.7, 47.9)
All four 51 2.0 (1.4, 2.6) 21 40.9 (27.6, 54.2)
∗∗
Percentages and 95% confidence intervals calculated using generalized estimating equations, with binary family, identity link, and exchangeable correlation.
among those women with bacterial vaginosis diagnosed by
clinical (Amsel) criteria (Prevalence 12.0%, 95% CI 8.2,
15.8), compared to those women who were not diagnosed
with bacterial vaginosis by clinical criteria (Prevalence 6.5%,
95% CI 5.3, 7.6). We did not find evidence of diﬀerences
in the prevalence of vulvovaginal candidiasis by other
laboratory diagnoses or behavioral characteristics (Table 3).
4. Discussion
We examined the incidence, prevalence, and potential risk
factors for vulvovaginal candidiasis among a cohort of
reproductive-age women in Mysore, India. Among this
cohort, we found evidence that a presumptive diagnosis of
vulvovaginal candidiasis based only on presence of signs or
symptoms, in absence of laboratory confirmation, would be
mostly incorrect. Consistent with previous research [24], we
could not identify behavioral risk factors for vulvovaginal
candidiasis, which provides impetus for additional investiga-
tion into intrinsic factors such as the composition of vaginal
flora, the presence or absence of genetic factors, and the
features of the host and local immune response.
Vaginal discharge, itching, and erythema, while quite
common, were insuﬃcient to diagnose vulvovaginal can-
didiasis in the absence of laboratory confirmation. Had
syndromic diagnosis been used to diagnose vulvovaginal
candidiasis in this cohort, the positive predictive values
would have been very low (15–41%). Our results are
consistent with other studies detailing the overtreatment
that results from the use of syndromic diagnosis based on
vaginal discharge to diagnose vaginal conditions [25–28].
Previous findings also demonstrate that aminority of women
with vaginal discharge have vulvovaginal candidiasis [25, 29–
31]. Thus, the diagnosis of vulvovaginal candidiasis based
solely on signs or symptoms leads to overestimation of the
prevalence of vulvovaginal candidiasis and its overtreatment,
while leaving the actual cause of the vaginal symptoms
untreated. This finding of misdiagnosis based on symptoms
is also relevant for women who self-diagnose vulvovaginal
candidiasis.
The prevalence of laboratory-confirmed vulvovaginal
candidiasis we observed is consistent with the results of two
other community-based studies in India [9, 10]. Given that
reproductive tract conditions account for nearly half of the
days of illness experienced among women in this region of
India [32], it is critical to understand the incidence and
prevalence of individual conditions; to our knowledge, this
is the first study from India to describe the incidence of and
possible risk factors for vulvovaginal candidiasis.
The study visit-specific point prevalence of vulvovaginal
candidiasis in this cohort decreased from 9% to 5%, and 72%
of treated women were negative for vulvovaginal candidiasis
at their next study visit, indicating successful provision
of treatment. Only 20% of those infected with Candida
were diagnosed as having vulvovaginal candidiasis, much
lower than the 53% found in a community-based study
in Tamil Nadu, India [9]. We were not able to determine
whether the 28% of women with a diagnosis of vulvovaginal
candidiasis on two consecutive visits were cases in which,
despite treatment, vulvovaginal candidiasis had cleared and
then recurred. More likely, the repeat diagnoses at consec-
utive visits represent instances in which the vulvovaginal
candidiasis was caused by Candida species not susceptible to
fluconazole treatment. Previous research in India has found a
high proportion of women infected by non-albicans Candida
species [29, 33], which are more resistant to treatment with
azoles [34, 35].
Of the sociodemographic and behavioral characteristics
we examined, only age at initiation of sexual activity
appeared to be associated with the prevalence of vulvovaginal
candidiasis, such that those with later initiation of sexual
activity had a higher prevalence of vulvovaginal candidiasis.
As the number of years women had been with their sex
partners was not associated with vulvovaginal candidiasis,
these two sociodemographic results appear discrepant and
warrant additional investigation.
We found a positive association between having clinically
diagnosed bacterial vaginosis and vulvovaginal candidiasis.
As both diagnoses include vaginal discharge as a component
of their respective diagnostic criteria, it is very likely there
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Table 3: Prevalence of vulvovaginal candidiasis by sociodemographic, behavioral, partner, and laboratory measures, Mysore, India 2005-
2006.
Prevalent vulvovaginal candidiasis (Overall prevalence = 180/2528; 7.1%)
Prevalence (n/N) Prevalence (%) Prevalence 95% CI
Age, years
16–20 14/157 9.2 (4.1, 14.3)
21–25 72/978 7.4 (5.4, 9.5)
26–30 94/1391 6.6 (5.2, 8.1)
Years of education
0 44/666 6.6 (4.3, 8.9)
1–7 59/767 7.7 (5.7, 9.7)
8–17 77/1095 7.0 (5.2, 8.8)
Years with sex partner
0–6 55/728 7.5 (5.3, 9.6)
7–19 124/1794 6.9 (5.6, 8.2)
Socioeconomic status∗∗∗
Low 79/1257 6.3 (4.8, 7.7)
High 101/1271 7.9 (6.1, 9.8)
Parity
No 22/361 6.0 (3.5, 8.5)
Yes 158/2164 7.3 (6.1, 8.5)
Religion∗
Non-Muslim 116/1805 6.4 (5.1, 7.7)
Muslim 64/721 8.9 (6.5, 11.3)
Age of initiation of sexual activity, years∗∗
<14 21/476 4.4 (2.6, 6.3)
15–18 110/1460 7.5 (6.1, 9.0)
19+ 49/590 8.2 (5.5, 11.0)
Number of vaginal sex acts in prior three
months
0–12 65/769 8.2 (6.0, 10.5)
13–120 115/1755 6.6 (5.4, 7.8)
Ever had anal sex
No 167/2358 7.1 (5.9, 8.2)
Yes 13/169 7.6 (3.6, 11.5)
Husband has other sex partners
No 167/2371 7.1 (6.0, 8.2)
Yes 13/157 7.8 (3.3, 12.4)
Tubal ligation
No 65/910 7.0 (5.3, 8.8)
Yes 115/1616 7.2 (5.7, 8.6)
Herpes simplex virus type 2 infection
Negative 156/2201 7.1 (5.9, 8.3)
Positive 24/327 6.9 (4.0, 9.8)
Trichomonas vaginalis infection
Negative 169/2383 7.1 (5.8, 8.3)
Positive 11/145 8.0 (3.4, 12.6)
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Table 3: Continued.
Prevalent vulvovaginal candidiasis (Overall prevalence = 180/2528; 7.1%)
Prevalence (n/N) Prevalence (%)
Prevalence
95% CI
Vaginal pH
<4.5 54/868 6.0 (4.3, 7.7)
≥4.5 126/1659 7.7 (6.4, 9.0)
Clinical (Amsel) criteria diagnosis for
bacterial vaginosis∗∗
Negative 145/2231 6.5 (5.3, 7.6)
Positive 35/296 12.0 (8.2, 15.8)
Laboratory (Nugent) criteria diagnosis for
bacterial vaginosis
Negative 116/1633 6.9 (5.6, 8.3)
Intermediate 36/373 9.8 (6.8, 12.8)
Positive 21/391 5.7 (3.1, 8.2)
Lactobacillus morphotypes detected∗
≥30 123/1594 7.5 (6.0, 9.0)
5–29 24/256 9.6 (5.9, 13.3)
1–4 4/118 3.7 (0.3, 7.0)
<1 5/134 4.5 (0.8, 8.2)
0 16/291 5.5 (2.6, 8.4)
Prevalences, 95% confidence intervals and P values calculated using generalized estimating equations with binary family, identity link, and exchangeable
correlation.
∗0.05 ≤ P < 0.10.
∗∗P < 0.05.
∗∗∗A socioeconomic index was calculated using the first factor from a principle components analysis of household consumer goods, toilet type, financial
instruments, and stove type, and then recoded into a binary score of low and high socioeconomic status [23].
is misclassification between vulvovaginal candidiasis and
clinically defined bacterial vaginosis. For example, women
infected with Candida may have discharge caused by
bacterial vaginosis and could thus be misdiagnosed with
vulvovaginal candidiasis [36]. Our findings emphasize the
problems inherent in making diagnoses of vaginal conditions
based on clinical examination alone [34, 37, 38].
We found some evidence that the prevalence of vulvo-
vaginal candidiasis varied with the presence of Lactobacillus
morphotypes. The evidence for a relationship between the
prevalence of vulvovaginal candidiasis and the presence of
Lactobacillus in the vagina is conflicting, including studies
in which the H2O2-production status of Lactobacillus was
considered [24, 39–44]. Recently, a prospective cohort study
of female sex workers in Kenya found the presence of Lacto-
bacillus, regardless of H2O2-production status, was positively
associated with prevalent vulvovaginal candidiasis (adjusted
odds ratio (aOR) 2.3, 95%CI 0.8, 6.4), a relationship that was
strengthened after restricting the analysis to women without
a diagnosis of bacterial vaginosis (aOR 3.8, 95% CI 1.3, 10.8)
[39].
The loss of vaginal Lactobacilli is the hypothesized medi-
ator for the relationship between the receipt of antibiotics
and the risk of vulvovaginal candidiasis [1, 5, 45, 46].
The mediation hypothesis also underpins the long-standing
interest in use of probiotic interventions to reduce the risk
of developing vulvovaginal candidiasis [1, 47, 48]; the results
here do not provide strong support for this hypothesis.
Strengths of this study include a large eﬀective sam-
ple size derived from the use of participants’ repeated
observations, which allows for measurements of prevalence
and incidence. Additionally, other studies of vulvovaginal
candidiasis in India use samples of symptomatic women
recruited from clinics or used syndromic diagnosis and
as a result were not able to estimate the community-level
prevalence of vulvovaginal candidiasis. Our study is one of
the few to examine the prevalence of vulvovaginal candidiasis
across a range in the number of Lactobacillus morphotypes
detected in the vagina; examination of a dose-response
provides better evidence, if any, of a biological relationship.
There are also important limitations of our study to
consider. First, the women in this cohort were recruited by
nonrandom sampling; unmeasured sampling bias can limit
the generalizability of these results. Second, because of the
cross-sectional nature of our analysis, we cannot make causal
interpretations for the variations in the prevalence of vulvo-
vaginal candidiasis observed here. Third, we were not able
to speciate the Candida organisms detected. The associations
between sociodemographic characteristics and potential risk
factors and the prevalence of vulvovaginal candidiasis may
diﬀer by the Candida species which infect women, which
are known to vary considerably by geographical location [1].
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Fourth, we could not verify whether participants were self-
medicating between visits with antibiotics or antifungals,
which would influence the incidence and prevalence mea-
surements of vulvovaginal candidiasis. Further, we could not
immediately followup with women treated for vulvovaginal
candidiasis, and so could not verify whether treatment
was successful. Finally, given the limited duration of the
study, we could not identify a subset of women with
recurrent vulvovaginal candidiasis, an important condition
with epidemiologic features distinct from acute vulvovaginal
candidiasis [49].
5. Conclusions
We found that syndromic diagnosis will result in sub-
stantial overdiagnosis and overtreatment of vulvovaginal
candidiasis-negative women. For correct diagnosis of vul-
vovaginal candidiasis laboratory confirmation of vaginal
infection with Candida is necessary as is a mean of assessing
whether the discharge has been caused by bacterial vaginosis.
Absent accurate means of diagnosing vulvovaginal candidi-
asis, women remain at risk for vulvovaginal candidiasis-
associated negative birth outcomes and acquisition of sexu-
ally transmitted infections. Follow-up studies are needed of
women infected with Candida yeast species to determine the
risk factors for the yeast’s overgrowth, as it appears that the
examination of behavioral risk factors does not appear to be
a fruitful avenue for further inquiry.
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